Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000532056 | SCV000648744 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2024-01-29 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 1464 of the ALK protein (p.Arg1464Gly). This variant is present in population databases (rs374135358, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with ALK-related conditions. ClinVar contains an entry for this variant (Variation ID: 470872). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002330928 | SCV002629862 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-01-29 | criteria provided, single submitter | clinical testing | The p.R1464G variant (also known as c.4390C>G), located in coding exon 29 of the ALK gene, results from a C to G substitution at nucleotide position 4390. The arginine at codon 1464 is replaced by glycine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |